SCHEMBL5047841

SCHEMBL5047841

O=C(NCCCn1ccnc1)c1cc(-n2cnnc2-c2cccc(F)c2F)c[nH]1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.53
CYP1A2 P05177 3/20 0.53
CYP3A4 P08684 3/20 0.53
CYP2D6 P10635 3/20 0.53
CYP2C9 P11712 3/20 0.53
CYP2C19 P33261 3/20 0.53
ALDH1A1 P00352 5/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 4/20 0.51
GAA P10253 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
POLB P06746 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 3/20 0.44
TSHR P16473 1/20 0.44
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14286125 0.77 ADORA2A (0.53) ADORA2ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14286129 0.77 ADORA2A (0.53) ADORA2ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14278766 0.74 CYP1A2 (0.53) ADORA2ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5037115 0.74 GSK3B (0.51) CYP1A2CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL14600751 0.70 GAA (0.46) ADORA2ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14600776 0.70 ALDH1A1 (0.46) ADORA2ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14600757 0.69 ALDH1A1 (0.44) ADORA2ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14286130 0.68 MAPK14 (0.40) ALDH1A1HTT
SCHEMBL14286170 0.67 CYP1A2 (0.51) ADORA2ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1179031 0.67 GLA (0.75) CYP3A4CYP2C19ALDH1A1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7314885-B2 Pyrrole compounds useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-01 US disclosed
US-7314885-B2 Pyrrole compounds useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-01 US disclosed
US-20060173055-A1 (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
EP-1660487-A1 PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET Vertex Pharmaceuticals Incorporated (US) 2006-05-31 EP disclosed
US-20050101650-A1 Pyrrole compositions useful as inhibitors of c-Met VERTEX PHARMACEUTICALS INCORPORATED 2005-05-12 US disclosed
WO-2005016920-A1 PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101650-A1 Pyrrole compositions useful as inhibitors of c-Met MET, PRKCH, DMPK ADORA2A 4126/4885CYP1A2 4341/4885CYP3A4 3798/4885
US-20060173055-A1 (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase MET, DMPK, CDK4 ADORA2A 4163/4885CYP1A2 2453/4885CYP3A4 1708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.